Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
51M
-
Shares change
-
+1.25M
-
Total reported value, excl. options
-
$1.11B
-
Value change
-
+$28M
-
Put/Call ratio
-
0.22
-
Number of buys
-
68
-
Number of sells
-
-40
-
Price
-
$21.77
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q3 2022
131 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q3 2022.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51M shares
of 69.8M outstanding shares and own 73.13% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (6.88M shares), BVF INC/IL (4.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.1M shares), WELLINGTON MANAGEMENT GROUP LLP (3.41M shares), BlackRock Inc. (3.2M shares), BAKER BROS. ADVISORS LP (2.88M shares), Redmile Group, LLC (2.88M shares), VANGUARD GROUP INC (2.86M shares), STATE STREET CORP (2.69M shares), and Avoro Capital Advisors LLC (2.17M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.